Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 658-664

  Alon, Uri S ^a   Levy Olomucki, Rachel ^a   Moore, Wayne V ^a   Stubbs, Jason ^b   Liu, Shiguang ^b   Quarles, L Darryl ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; CREATININE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM DERIVATIVE; POTASSIUM DIHYDROGEN PHOSPHATE; VITAMIN;

ADOLESCENT; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CALCIFICATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; X LINKED HYPOPHOSPHATEMIC RICKETS;

ADMINISTRATION, ORAL; ADOLESCENT; CALCITRIOL; CALCIUM; CHILD; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MALE; NAPHTHALENES; NEPHROCALCINOSIS; PARATHYROID HORMONE; PHOSPHATES; POTASSIUM COMPOUNDS; TREATMENT OUTCOME; VITAMINS;

EID: 44649135371     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04981107     Document Type: Article

References (43)

1. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets: the HYP Consortium. Nat Genet 11: 130-136, 1995
2. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002
3. Jonsson KB, Zahradnik R, Larsson T, Whithe KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 1656-1663, 2003
4. Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6506, 2001
6. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
7. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of FGF23 in Hyp mice. Am J Physiol Endrocrinol Metab 291: E38-E49, 2006
8. Baroncelli GI, Bertelloni S, Sodini F, Galli L, Vanacore T, Fiore L, Saggese G: Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev 1: 361-379, 2004
9. Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y: A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58: 329-333, 2005
10. Alon US: Hypophosphatemic vitamin D-resistant rickets. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed, Washington, DC, American Society for Bone and Mineral Research, 2006:342-345
11. Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ: Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 120: 899-905, 1992
12. Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner ME, Yadin O: Hypertension in hypophosphatemic rickets: role of secondary hyperparathyroidism. Pediatr Nephrol 18: 155-158, 2003
13. Makitie O, Doria A, Koch SW, Cole WG, Daneman A, Sochett E: Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88: 3591-3597, 2003
14. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez Cruz L, Campistol JM, Torres A, Rodriguez M: High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 9: 1845-1852, 1998
15. Savic, RM, Gosnell JE, Posen S, Reeve TS, Delbridge LW: Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg 139: 218-222, 2004
16. McHenry CR, Mostafavi D, Murphy TA: Tertiary hyperparathyroidism attributable to long-term oral phosphate therapy. Endocr Pract 12: 294-298, 2006
17. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA: Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005
18. Burnett SM, Gunawardene SC, Bringhurst FB, Jüppner H, Lee H, Finkelstein FS: Regulation of C-terminal and intact FGF23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006
19. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK: Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D. J Bone Miner Res 20: 1944-1950, 2005
20. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
21. Hammerland LG, Garrett JE, Hung BC, Levinthal C, Nemeth EF: Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53: 1083-1088, 1998
22. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95: 4040-4045, 1998
23. Nemeth EF, Bennett SA: Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 13: 1923-1925, 1998
24. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 5644-5649, 2003
25. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
26. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT: Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 44: 1070-1076, 2004
27. Goodman WG: Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 18: 1206-1210, 2003
28. Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucc CM, Meier-Kriesche HU: Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Neprol 1: 323-326, 2006
29. Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT: Clinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22: 931-937, 2007
30. Alon U, Hellerstein S: Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 8: 250-251, 1994
31. Schiavi SC: Fibroblast growth factor 23: the making of a hormone. Kidney Int 69: 425-427, 2006
32. Nagano N, Miyata S, Kobayashi N, Wakita S, Yamashita T, Wada M: Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rates. Kidney Int 69: 531-537, 2006
33. Mirams M, Robinson BG, Mason RS, Nelson AE: Bone as a source of FGF23: regulation by phosphate? Bone 35: 1192-1199, 2004
34. Kolek IO, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK: 1apha 25-dihydrovitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005
35. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N: Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005
36. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE: Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36: 971-977, 2005
37. Verge CF, Lam A, Simpson JM, Cowell CT, Hoeard NJ, Silink M: Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325: 1843-1848, 1991
38. Agus ZS, Puschett JB, Senesky D, Goldberg M: Mode of action of parathyroid hormone and cyclic adenosine 3′,5′-monophosphate on renal tubular phosphate reabsorption in the dog. J Clin Invest 50: 617-626, 1971
39. Favus MJ, Bushinsky DA, Lemann JJ: Regulation of calcium, magnesium, and phosphate metabolism. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed, Washington, DC, American Society for Bone and Mineral Research, 2006:76-83
40. Alon U, Chan JC: Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets. J Clin Endocrinol Metab 58: 671-675, 1984
41. Chertow CM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J: Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin-D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 1: 305-312, 2006
42. Quarles LD: Cincalcet HCI: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int 68[Suppl]: S24-S28, 2005
43. Bushinsky DA, Laplante K, Asplin JR: Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int 69: 1586-1592, 2006